John Boniface
Chief Tech/Sci/R&D Officer chez SERA PROGNOSTICS, INC.
Fortune : 1 M $ au 31/03/2024
Postes actifs de John Boniface
Sociétés | Poste | Début | Fin |
---|---|---|---|
SERA PROGNOSTICS, INC. | Chief Tech/Sci/R&D Officer | 01/11/2011 | - |
Historique de carrière de John Boniface
Anciens postes connus de John Boniface
Sociétés | Poste | Début | Fin |
---|---|---|---|
Bioinformatics Solutions, Inc.
Bioinformatics Solutions, Inc. Packaged SoftwareTechnology Services Bioinformatics Solutions, Inc. develops and innovate PEAKS software platform. The firm products are discovery, antibody based, and PEAKS components identify and quantify proteins in very complex biological samples with LC-MS. It also focused on serving the proteomics research community. The company was founded in 2000 and is headquartered in Waterloo, Canada. | Chief Tech/Sci/R&D Officer | - | - |
EOS Biotechnology, Inc.
EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California. | Corporate Officer/Principal | - | - |
MYRIAD GENETICS, INC. | Corporate Officer/Principal | - | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Corporate Officer/Principal | - | - |
MYREXIS, INC. | Corporate Officer/Principal | - | - |
Formation de John Boniface
University of Massachusetts | Undergraduate Degree |
Albany Medical College | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 8 |
Canada | 2 |
Opérationnelle
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
MYRIAD GENETICS, INC. | Health Technology |
MYREXIS, INC. | Finance |
SERA PROGNOSTICS, INC. | Health Services |
Entreprise privées | 3 |
---|---|
EOS Biotechnology, Inc.
EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California. | Health Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
Bioinformatics Solutions, Inc.
Bioinformatics Solutions, Inc. Packaged SoftwareTechnology Services Bioinformatics Solutions, Inc. develops and innovate PEAKS software platform. The firm products are discovery, antibody based, and PEAKS components identify and quantify proteins in very complex biological samples with LC-MS. It also focused on serving the proteomics research community. The company was founded in 2000 and is headquartered in Waterloo, Canada. | Technology Services |
- Bourse
- Insiders
- John Boniface
- Expérience